<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931303</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT04931303</nct_id>
  </id_info>
  <brief_title>Digital GaitCare - Therapy Monitoring in the Home Environment of Patients With Parkinson</brief_title>
  <official_title>Digital GaitCare - Therapy Monitoring in the Home Environment of Patients With Parkinson Via Digital Gait Analysis and Patient Feedback</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Valley Digital Health Application Center GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Rummelsberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NeuroPoint GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Portabiles HealthCare Technologies GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Systemhaus Ulm GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fraunhofer Institute for Integrated Circuits IIS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Friedrich-Alexander-Universit채t Erlangen-N체rnberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leibniz Centre for European Economic Research GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical Valley Digital Health Application Center GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gait disturbances and movement restrictions occur frequently in Parkinson's disease.&#xD;
      Patient-centered monitoring with objective aids in the patient's daily life, supports and&#xD;
      promotes therapy decisions made by physicians and patients. Technical, sensor-based&#xD;
      monitoring has the potential to generate objective target parameters at any point in time&#xD;
      during therapy (patient journey), representing the state of health and its progression, and&#xD;
      to make this information available to physicians and patients via telemedical data&#xD;
      management. In this study, the gait analysis system &quot;Mobile GaitLab Home 2.0&quot;, consisting of&#xD;
      sensors for gait data acquisition, a smartphone application for study participants (Mobile&#xD;
      GaitLab app) and a web portal for physicians (Mobile GaitLab portal) is used for data&#xD;
      collection.&#xD;
&#xD;
      The research question is divided into three sub-objectives: First, the study explores and&#xD;
      tests how technically generated parameters of sensor-based gait analysis can map the symptom&#xD;
      &quot;bradykinesis&quot;. The second goal is the explorative investigation of how a tele-health service&#xD;
      support with low-threshold access to medical professionals, can be integrated into the care&#xD;
      process. The third goal is the implementation evaluation of the technological developments.&#xD;
      Here, it is examined to determine the extent to which the implementation of gait data and&#xD;
      patient feedback (PROMs) in the patient-centered care process within the framework of&#xD;
      clinical decision support contributes to early gait-associated therapy optimization and thus&#xD;
      improves the general health of patients and how initial indications of positive care effects&#xD;
      for patients can be derived.&#xD;
&#xD;
      During a 60-day observation phase, study participants use the gait analysis system, which&#xD;
      records their gait pattern throughout the day and collects data via the Mobile GaitLab app.&#xD;
      Study participants are asked to perform standardized gait tests in the home environment&#xD;
      several times a day, in addition to continuous measurements during the awake phase. Frequency&#xD;
      of data collection is controlled by Mobile GaitLab Home 2.0 and can be flexibly adjusted to&#xD;
      the study participant's health status and therapy. The Mobile GaitLab app uses questionnaires&#xD;
      to record data on gait safety, activity, general well-being, and events relevant to the&#xD;
      disease. An evaluation of these data (PROMs) and the results from the gait analyses, are&#xD;
      visualized for the study participants via the Mobile GaitLab app.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in gait parameters (stride length) during 4x10 meter gait test (4x10m) performed at clinic</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in stride length in cm during 4x10m performed at clinic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in gait parameters (stride time) during 4x10 meter gait test (4x10m) performed at clinic</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in stride time in seconds during 4x10m performed at clinic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in gait parameters (gait speed) during 4x10 meter gait test (4x10m) performed at clinic</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in gait speed in m/s during 4x10m performed at clinic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in gait parameters (heel-strike angle) during 4x10 meter gait test (4x10m) performed at clinic</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in heel-strike angle in degree during 4x10m performed at clinic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in gait parameters (toe-off angle) during 4x10 meter gait test (4x10m) performed at clinic</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in toe-off angle in degree during 4x10m performed at clinic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in gait parameters (foot-clearance) during 4x10 meter gait test (4x10m) performed at clinic</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in foot clearance in cm during 4x10m performed at clinic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in gait parameters (variability) during 4x10 meter gait test (4x10m) performed at clinic</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in variability in percent during 4x10m performed at clinic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in time of 1 x 10 meter gait test (1x10m) performed at baseline versus closeout</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in time, measured in seconds of 6 meter constant walking within the 10-meter gait test at baseline and at closeout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in time of Timed-Up-and-Go Test (TUG) performed at baseline versus closeout</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in time, measured in seconds of TUG at baseline and at closeout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Unified Parkinson's Disease Rating Scale III (UPDRS III) Motor Score evaluated at baseline versus closeout</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in UPDRS III Motor Score (range from 0 to 56, Lower scores mean a better outcome) at baseline and at closeout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Shared-Decision-Making-Questionaire-9 (SDM-Q9) evaluated at baseline versus closeout</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in SDM-Q9 (range from 0 to 45, Higher scores mean a better outcome) at baseline and at closeout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Parkinsons-Disease-Questionaire (PDQ-39) evaluated at baseline versus closeout</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in PDQ-39 (range from 0 to 100, Lower scores mean a better outcome) at baseline and at closeout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Parkinson-specific-health-literacy evaluated at baseline versus closeout</measure>
    <time_frame>day 1 and day 60</time_frame>
    <description>Difference in Parkinson-specific-health-literacy (range from 0 to 100, Higher scores mean a better outcome) at baseline and at closeout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of useful Patient-Physician-Contacts evaluated at closeout</measure>
    <time_frame>day 60</time_frame>
    <description>Counted number of useful Patient-Physician-Contacts during study duration (range from 0 to individual number of Patient-Physician-Contacts) evaluated at closeout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>System Usability Scale (SUS) and modified SUS evaluated at closeout</measure>
    <time_frame>day 60</time_frame>
    <description>SUS score per patient - range from 0 to 100 score points (Higher scores mean a better outcome.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collecting gait parameters (stride length) during gait tests and monitoring at home</measure>
    <time_frame>day 1 to day 60</time_frame>
    <description>Collection of gait parameters (stride length in cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collecting gait parameters (stride time) during gait tests and monitoring at home</measure>
    <time_frame>day 1 to day 60</time_frame>
    <description>Collection of gait parameters (stride time in seconds)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collecting gait parameters (gait speed) during gait tests and monitoring at home</measure>
    <time_frame>day 1 to day 60</time_frame>
    <description>Collection of gait parameters (gait speed in m/s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collecting gait parameters (heel-strike angle) during gait tests and monitoring at home</measure>
    <time_frame>day 1 to day 60</time_frame>
    <description>Collection of gait parameters (heel-strike angle in degree)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collecting gait parameters (toe-off angle) during gait tests and monitoring at home</measure>
    <time_frame>day 1 to day 60</time_frame>
    <description>Collection of gait parameters (toe-off angle in degree)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collecting gait parameters (foot clearance) during gait tests and monitoring at home</measure>
    <time_frame>day 1 to day 60</time_frame>
    <description>Collection of gait parameters (foot clearance in cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collecting gait parameters (variability) during gait tests and monitoring at home</measure>
    <time_frame>day 1 to day 60</time_frame>
    <description>Collection of gait parameters (variability in percent)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Gait Disorders, Neurologic</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Enrolled patients receive a medical device which monitors gait quality and collects information about the patients health status. Possible changes of intervention (drug or physical therapy) within the observational phase (8 weeks) are initiated and prescribed by physicians as a result of routine care process or patient contact based on their (deteriorated) health status. With the chosen endpoints, changes of patients empowerment, gait quality and system usability by using a monitoring device are monitored.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be enrolled during their routine outpatient or physician visit or&#xD;
        inpatient stay.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic Parkinson's disease (H&amp;Y I-IV)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Ability to walk &gt; 4 x 10 m without assistance&#xD;
&#xD;
          -  Ability to speak and read&#xD;
&#xD;
          -  Ability to use an application that can be mapped on a smart device&#xD;
&#xD;
          -  Informed consent of the study participant&#xD;
&#xD;
          -  Willingness of the study participant to take therapy measures (e.g., medication&#xD;
             therapy, exercise therapy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tremor-dominant Parkinson's syndrome without involvement of the lower extremities&#xD;
&#xD;
          -  Aphasia and alexia&#xD;
&#xD;
          -  Visual disturbances that make reading impossible&#xD;
&#xD;
          -  Higher-grade movement disorders, with high risk of falls and non-independent ability&#xD;
             to walk&#xD;
&#xD;
          -  Higher grade cognitive deficits&#xD;
&#xD;
          -  Inability of the study participant to understand the information and procedures of the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J체rgen Winkler, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Molekulare Neurologie, Universit채tsklinikum Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Stallforth, PhD</last_name>
    <phone>09131 85-39324</phone>
    <email>sabine.stallforth@uk-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Philipps University Marburg Medical Center</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Rummelsberg</name>
      <address>
        <city>Schwarzenbruck</city>
        <zip>90592</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neuropoint GmbH</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>Gait Analysis</keyword>
  <keyword>Digital Health</keyword>
  <keyword>Home-Monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Gait Disorders, Neurologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

